Abstract LB147: Updates on clinical safety and efficacy result of GC027, the first-in-human, “Off-the-Shelf” CD7 CAR-T stand-alone therapy for adult patients with relapsed/refractory T-cell lymphoblastic leukemia (r/r T-ALL)
Shiqi Li(University of Science and Technology of China), Xi Zhang(Army Medical University), Martina Sersch(Innovacell Biotechnologie (Austria)), Zhongtao Yuan, Zhimin Li(Innovacell Biotechnologie (Austria)), Ruihao Huang(Army Medical University), Sanbin Wang(117th Hospital of People's Liberation Army), Yu Li(Zhejiang Chinese Medical University), Lin Liu(Wuxi People's Hospital), Jia Liu(Frederick National Laboratory for Cancer Research), Cheng Zhang(Salk Institute for Biological Studies), Yao Liu(Chongqing University), Le Luo(Central South University), Kun Wu(Kunming Medical University), Lei Gao(Zhejiang Chinese Medical University), Youcheng Wang, Xinxin Wang, Xu Tan(Army Medical University), Duanpeng Wang, Dingsong Zhang
Cited by 4
Related Papers
Development of a primary human Small Intestine-on-a-Chip using biopsy-derived organoids
|Scientific Reports|2018|736
Recent advances in CAR-T cell engineering
|Journal of Hematology & Oncology|2020|403
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|234
HDAC6 Is Required for Epidermal Growth Factor-induced β-Catenin Nuclear Localization
|Journal of Biological Chemistry|2008|174
TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair
|Frontiers in Oncology|2019|115